Table 3 The clinicopathological features and the expression of ZEB1 in patients with breast cancer
Clinicopathological feature | ZEB1 | Cases | χ2 | p | |
|---|---|---|---|---|---|
Positive | Negative | ||||
Age | |||||
 < 50 | 52 (78.8%) | 14 (21.2%) | 66 | 0.237 | 0.627 |
 ≥ 50 | 39 (75.0%) | 13 (25.0%) | 52 | ||
Tumor size | |||||
 < 2 cm | 29 (80.6%) | 7 (19.4%) | 36 | 0.347 | 0.556 |
 ≥ 2 cm | 62 (75.6%) | 20 (24.4%) | 82 | ||
LNM | |||||
 No | 41 (87.2%) | 6 (12.8%) | 47 | 4.529 | 0.003 |
 Yes | 50 (70.4%) | 21 (29.6%) | 71 | ||
Infiltrating breast cancer | 36 (67.9%) | 17 (32.1%) | 53 | 6.460 | 0.011 |
Ductal carcinoma in situ | 21 (100.0%) | 0 (0.0%) | 21 | 0.977 | 0.323 |
Node-positive breast cancer | 13 (67.9%) | 9 (40.9%) | 22 | 8.282 | 0.004 |
Paracancerous tissues | 21 (95.5%) | 1 (4.5%) | 22 | Â | Â |